Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 02/06/2023)

1st line
BO44178 (Roche)
A Study of RO7247669 Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer. 
(Temporarily on hold for adenocarcinoma)

ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of  PDC*Lung01 Cancer Vaccine in NSCLC.
(cohort B2 open)

ARTEMIDE-01 (AstraZeneca)
Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer.
(cohort D open) 


2nd line 
CARMEN-LC03 (Sanofi) (after chemo- and immunotherapy)
SAR408701 (tusamitamab ravtansine; ADC) Versus Docetaxel in Previously Treated CEACAM5 Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients.

CARMEN-LC06 (Sanofi) (after chemo- and immunotherapy)
Open label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine (ADC) in participants with CEACAM5 negative-moderate expression and high circulating CEA non-squamous non-small-cell lung cancer (NSQ NSCLC).

ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

Aurelio-04 (Sotio) (after chemo- and/or immunotherapy)
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors. 
(Temporarily on hold)

3rd line
ImmunoSABR (Academic) 
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.